Amgen Presents Data on Vectibix/Chemo Efficacy in Wild-Type KRAS Colorectal Cancer Patients | GenomeWeb

By Turna Ray

Amgen this week presented new data that not only provides further evidence that Vectibix is not efficacious in metastatic colorectal cancer patients with certain KRAS mutations, but also suggests that the company may attempt to expand the indication for the drug.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.